[go: up one dir, main page]

WO2024036186A2 - Identification de séquences cibles spécifiques d'allèles pour c9orf72 - Google Patents

Identification de séquences cibles spécifiques d'allèles pour c9orf72 Download PDF

Info

Publication number
WO2024036186A2
WO2024036186A2 PCT/US2023/071895 US2023071895W WO2024036186A2 WO 2024036186 A2 WO2024036186 A2 WO 2024036186A2 US 2023071895 W US2023071895 W US 2023071895W WO 2024036186 A2 WO2024036186 A2 WO 2024036186A2
Authority
WO
WIPO (PCT)
Prior art keywords
aso
c90rf72
nucleotides
cell
nucleic acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2023/071895
Other languages
English (en)
Other versions
WO2024036186A3 (fr
Inventor
John Edward LANDERS
Desiree Marie POWELL
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Massachusetts Boston
University of Massachusetts Amherst
Original Assignee
University of Massachusetts Boston
University of Massachusetts Amherst
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Massachusetts Boston, University of Massachusetts Amherst filed Critical University of Massachusetts Boston
Priority to EP23853497.8A priority Critical patent/EP4569116A2/fr
Publication of WO2024036186A2 publication Critical patent/WO2024036186A2/fr
Publication of WO2024036186A3 publication Critical patent/WO2024036186A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/712—Nucleic acids or oligonucleotides having modified sugars, i.e. other than ribose or 2'-deoxyribose
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/323—Chemical structure of the sugar modified ring structure
    • C12N2310/3231—Chemical structure of the sugar modified ring structure having an additional ring, e.g. LNA, ENA
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/34—Spatial arrangement of the modifications
    • C12N2310/341—Gapmers, i.e. of the type ===---===
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C12N2320/34—Allele or polymorphism specific uses

Definitions

  • ALS Amyotrophic Lateral Sclerosis
  • C9ORF72 A repeat expansion within the first intron of C9ORF72 represents the most common genetic cause of ALS and is also implicated as a common genetic cause of frontotemporal dementia (FTD). There is need for therapeutics that inactivate the effects of this repeat expansion.
  • a method of inhibiting expression of a C90rf72 gene comprising a two-base pair deletion in a cell comprises delivering to the cell an antisense oligonucleotide (ASO) that targets a C90rf72 allele comprising the two-base pair deletion.
  • ASO antisense oligonucleotide
  • the cell is in vitro.
  • the cell is in vivo.
  • the cell is heterozygous for the two-base pair deletion in C90rf72.
  • the cell is a human cell.
  • the cell is a cell of the central nervous system, optionally a neuron. [0004] In some embodiments, the cell is from a subject having one or more symptoms of ALS and/or FTD. In some embodiments, the cell is from a subject having or suspected of having ALS and/or FTD.
  • Some aspects of the disclosure comprise a method of inhibiting expression of a C90rf72 gene comprising a two-base pair deletion in the central nervous system (CNS) of a subject.
  • a method of inhibiting expression of a C90rf72 gene comprising a two-base pair deletion in the CNS of a subject comprises administering to the subject an ASO that targets a C90rf72 allele comprising the two-base pair deletion.
  • a method of treating a subject having or suspected of having ALS and/or FTD comprises administering to the subject an ASO that targets a C90rf72 allele comprising a two-base pair deletion.
  • an ASO comprising a nucleic acid sequence 10 to 25 nucleotides in length that is complementary with at least 8 contiguous nucleotides of any one of SEQ ID NOs: 2-22.
  • the ASO comprises the nucleic acid sequence of any one of SEQ ID NOs: 23-57.
  • FIG. 1 provides a schematic showing the sequence of the two-base pair deletion (C9-deletion, C9-del) that is in linkage disequilibrium with the C90rf72 repeat expansion relative to the wild-type sequence (See, SEQ ID NOs. 1 (WT) and 2 (C9-deletion)). Provided below the sequences are representative ASOs designed by 1-base pair tiling over the C9-deletion site.
  • FIG. 2 provides a graph showing the ability of ASOs that target the two-base pair deletion site to inhibit expression of C90rf72 in fibroblasts that are homozygous for an allele hosting the two-base pair deletion (C9-del/C9-del) compared to cells that are homozygous for the wild-type allele (WT/WT).
  • FIG. 3A provides a schematic for a dual luciferase assay.
  • FIG. 3B provides a schematic for the vector used in a dual luciferase assay.
  • FIGs. 4A-4C provide graphs showing the ability of MOE gapmer ASOs to inhibit expression of a C90rf72 target region in HEK cells.
  • ASOs were tested on cells expressing just the luciferase assay vector (no target region expressed), the luciferase vector carrying the wildtype sequence of the indel resistant to the ASOs (Normal Allele), and the luciferase vector carrying the C9-deletion sequence susceptible to the ASOs (Mutant Allele). Desired ASOs should repress expression of the C9-deletion target sequence and have little to no effect on the WT target sequence.
  • FIG. 5 provides a graph showing the ability of a MOE gapmer ASO to inhibit expression of C90rf72 in an allele- specific manner in fibroblasts.
  • FIGs. 6A-6C provide graphs showing the ability of LNA gapmer ASOs to inhibit expression of a C90rf72 target region in HEK cells.
  • ASOs were tested on cells expressing just the luciferase assay vector (no target region expressed), the luciferase vector carrying the wildtype sequence of the indel resistant to the ASOs (Normal Allele), and the luciferase vector carrying the C9-deletion sequence susceptible to the ASOs (Mutant Allele). Desired ASOs should repress expression of the C9-deletion target sequence and have little to no effect on the WT target sequence.
  • FIG. 7 provides a graph showing the ability of an LNA gapmer ASO to inhibit expression of C90rf72 in an allele- specific manner in fibroblasts.
  • FIG. 8 shows the location of the C9 Deletion Variant and a second variant located within the C90rf72 transcribed region.
  • FIG. 9A-9B provide graphs showing partial rescue of C90rf72 RNA foci formation in heterozygous patient C90rf72 fibroblasts treated with the allele specific LNA gapmer ASO #9.
  • aspects of the disclosure relate to methods for altering RNA splicing and/or inhibiting gene or protein expression in a cell or subject, particularly gene or protein expression of alleles comprising a genetic mutation.
  • Some embodiments of the disclosure provide mutantspecific knockdown/inhibition techniques that are designed to preferentially reduce expression (e.g., gene and/or protein expression) of a mutant allele relative to a wild-type allele.
  • the techniques of the disclosure described herein directly target the mutant allele comprising the genetic mutation instead of targeting both the mutant and the wild-type alleles, which is the strategy utilized by previous approaches in the art. This is important because it means that the techniques described herein do not significantly impact expression of wild-type alleles.
  • the disclosure provides compositions and methods for inhibiting gene or protein expression of C90rf72.
  • dysregulated C90rf72 2T expression is associated with ALS or FTD.
  • aspects of the disclosure relate to improved gene therapy compositions and related methods for treating ALS or FTD using antisense oligonucleotides that target a C90rf72 mutant allele (e.g., a mutant allele comprising a two-base pair deletion and a G4C2 repeat expansion).
  • the inventors of the disclosure have discovered that directly targeting indels (genetic insertions or deletions) can achieve the highest level of allele discrimination, which eliminates need for directly targeting repeat expansions or single point mutations/variants.
  • directly targeting indels gene insertions or deletions
  • C9- deletion a two-base pair deletion
  • the C90rf72 sequence variation comprising a two-base pair C9-deletion comprises SEQ ID NO: 2.
  • the C9-deletion polymorphism indel is located within the transcribed region of the C90rf72 gene.
  • an allele from the indel is often located on the same haplotype of the repeat expansion of C90rf72 (e.g., in linkage disequilibrium with G4C2 repeats).
  • the variant sequences of each indel are often present in a heterozygous state within C90rf72 patients.
  • the allele of each indel represents a target for allele- specific ASOs or similar knockdown technology.
  • indels are advantageous in developing allelespecific ASO due to difference of the targeted allele and the non-targeted allele.
  • SNPs single nucleotide polymorphisms within the C9ORF72 gene region which contain an allele that is commonly found on the same haplotype as the repeat expansion. These SNPs are located at r positions as follows: rs2453565, rs700828, rs774356, rs774357, rs774359, rs2453554, rs2484319, rs2453555, rs2492816, and rs3849945.
  • the two base pair C9-deletion is named rs 142843265.
  • the RS position naming convention is as described in Smith, B.N. et al., The C9ORF72 expansion mutation is a common cause of ALS +/- FTD in Europe and has a single founder. European Journal of Human Genetics (2013) 21, 102-108.
  • the disclosure provides inhibitory nucleic acids (e.g., ASOs) that inhibit expression of a C90rf72 gene comprising a mutated C90rf72 allele comprising a two-base pair deletion.
  • a mutated C90rf72 allele 2T comprises a mutated C90rf72 sequence having a two-base pair deletion.
  • the novel, mutated C90rf72 allele comprising a two-base pair deletion comprises SEQ ID NO: 2.
  • the inhibitory nucleic acids such as ASOs may, in some embodiments, preferentially inhibit (e.g., reduce expression of) a C90rf72 allele comprising a two-base pair C9-deletion relative to a wild-type C90rf72 allele.
  • the C90rf72 allele comprises G4C2 repeat expansions of up to 50, up to 90, up to 160, or up to 200 repeats.
  • the two-base pair C9-deletion is in linkage disequilibrium with G4C2 repeats.
  • the C90rf72 allele (e.g., comprising a two-base pair C9-deletion) comprises greater than 30, greater than 50, greater than 90, greater than 160, greater than 200, greater than 500 or greater than 1000 G4C2 repeats.
  • the two-base pair C9-deletion is in linkage disequilibrium with the G4C2 repeat expansions.
  • an inhibitory nucleic acid is an AS.
  • AS antisense oligonucleotide
  • ASO antisense nucleic acid
  • An ASO is specifically hybridizable when binding of the ASO to the target nucleic acid is sufficient to produce complementary based pairing between the ASO and the target nucleic acid, and there is a sufficient degree of complementarity to avoid non-specific binding of the ASO to non-target nucleic acid under conditions in which specific binding is desired, e.g., under physiological conditions in the case of in vivo assays or therapeutic treatment, and in the case of in vitro assays, under conditions in which the assays are performed.
  • an ASO is a single-stranded oligonucleotide.
  • the inhibitory nucleic acid is complementary to a segment of the mutated C90rf72 sequence having a two-base pair deletion comprising or consisting of the nucleic acid sequence of any one of SEQ ID NOs: 2-22.
  • the inhibitory nucleic acid comprises or consists of a sequence of nucleobases that are at least 80%, 90%, or 100% complementary to the nucleic acid sequence of any one of SEQ ID NOs: 2-22.
  • the ASO comprises or consists of the nucleic acid sequence of any one of SEQ ID NOs: 23-57.
  • the inhibitory nucleic acid has a stronger binding affinity for a mutated C90rf72 sequence comprising a two-base pair deletion and a G4C2 repeat expansion relative to a wild-type C90rf72 sequence.
  • the inhibitory nucleic acid may have a stronger binding affinity for a nucleic acid comprising SEQ ID NO: 2 relative to a nucleic acid comprising SEQ ID NO: 1.
  • the inhibitory nucleic acid has a binding affinity for a mutated C90rf72 sequence comprising a two-base pair deletion and a G4C2 repeat 2T expansion that is at least two-fold, three-fold, four-fold, or five-fold stronger than its binding affinity for a wild-type sequence without the two-base pair deletion.
  • the inhibitory nucleic acid has a binding affinity for a mutated C90rf72 sequence comprising a two- base pair deletion and a G4C2 repeat expansion that is at least 5%, 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, or 100% stronger than its binding affinity for a wild-type sequence without the two-base pair deletion.
  • a binding affinity may be measured using fluorescencebased methods, single-molecule kinetic methods, or any other binding assay known to a person of skill in the art.
  • the inhibitory nucleic acid inhibits or reduces expression levels (e.g., protein expression, gene expression, RNA expression, and the like) of a mutated C90rf72 allele (e.g., comprising a two-base pair deletion and a G4C2 repeat expansion) in a cell (e.g., a cell of the central nervous system) or a subject.
  • expression levels e.g., protein expression, gene expression, RNA expression, and the like
  • a mutated C90rf72 allele e.g., comprising a two-base pair deletion and a G4C2 repeat expansion
  • the inhibitory nucleic acid inhibits or reduces expression levels (e.g., protein expression, gene expression, RNA expression, etc.) of a mutated C90rf72 allele (e.g., comprising a two-base pair deletion and a G4C2 repeat expansion) by at least 5%, 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, or 100%, relative to a control (e.g., a baseline measurement or a control subject that is not administered the inhibitory nucleic acid).
  • a control e.g., a baseline measurement or a control subject that is not administered the inhibitory nucleic acid.
  • the inhibitory nucleic acid inhibits or reduces expression levels of a mutated C90rf72 allele (e.g., comprising a two-base pair deletion and a G4C2 repeat expansion) but does not substantially inhibit or reduce expression levels of wild-type C90rf72.
  • a mutated C90rf72 allele e.g., comprising a two-base pair deletion and a G4C2 repeat expansion
  • the inhibitory nucleic acid inhibits or reduces expression levels of a mutated C90rf72 allele (e.g., comprising a two-base pair deletion and a G4C2 repeat expansion) by at least 5%, 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, or 100%, relative to a control (e.g., a baseline measurement or a control subject that is not administered the inhibitory nucleic acid).
  • a control e.g., a baseline measurement or a control subject that is not administered the inhibitory nucleic acid.
  • the inhibitory nucleic acid inhibits or reduces expression levels of a mutated C90rf72 allele (e.g., comprising a two-base pair deletion and a G4C2 repeat expansion) by at least 5%, 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, or 100%, relative to wild-type C90rf72.
  • a mutated C90rf72 allele e.g., comprising a two-base pair deletion and a G4C2 repeat expansion
  • the inhibitory nucleic acid is 5 to 30 bases in length (e.g., 10-30, 15-25, 19-22).
  • the inhibitory nucleic acid may also be 10-50, or 5-50 bases length.
  • the inhibitory nucleic acid may be one of any of 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, or 50 bases in length.
  • the inhibitory nucleic acid comprises or consists of a sequence of bases at least 80% or 90% complementary to, e.g., at least 5, 10, 15, 20, 25 or 30 bases of, or up to 30 or 40 bases of, the target nucleic acid, or 2T comprises a sequence of bases with up to 3 mismatches (e.g., up to 1, or up to 2 mismatches) over 10, 15, 20, 25 or 30 bases of the target nucleic acid.
  • any one or more thymidine (T) nucleotides or uridine (U) nucleotides in a sequence provided herein may be replaced with any other nucleotide suitable for base pairing (e.g., via a Watson-Crick base pair) with an adenosine nucleotide.
  • T may be replaced with U
  • U may be replaced with T.
  • inhibitory nucleic acids are provided that inhibit expression of genes in a cell of the central nervous system.
  • the cell is a neuron, astrocyte, or oligodendrocyte.
  • the cell expresses a mutated C90rf72 allele (e.g., comprising a two-base pair deletion and a G4C2 repeat expansion) having G4C2 repeat expansions of up to 50, up to 90, up to 160, up to 200, up to 300, up to 400, up to 500 repeats, up to 600 repeats or more.
  • a mutated C90rf72 allele e.g., comprising a two-base pair deletion and a G4C2 repeat expansion
  • G4C2 repeat expansions of up to 50, up to 90, up to 160, up to 200, up to 300, up to 400, up to 500 repeats, up to 600 repeats or more.
  • the cell expresses a mutated C90rf72 allele (e.g., comprising a two-base pair deletion and a G4C2 repeat expansion) having G4C2 repeat expansions of 30 to 50 G4C2 repeats, 30 to 100 G4C2 repeats, 30 to 150 G4C2 repeats, 30 to 200 G4C2 repeats, 50 to 200 G4C2 repeats, 100 to 300 G4C2 repeats, 100 to 500 G4C2 repeats, 250 to 1000 G4C2 repeats, or more than 1000 G4C2 repeats.
  • the cell contains detectable levels of intranuclear G4C2 foci.
  • the cell contains detectable levels of C9 RAN proteins.
  • an ASO has a region of complementarity that is perfectly complementary to a portion of a target nucleic acid (e.g., target RNA).
  • a target nucleic acid e.g., target RNA
  • an ASO may be used that has less than 100% sequence complementarity with a target nucleic acid.
  • the region of complementarity of the ASO may be complementary with at least 6, e.g., at least 7, at least 8, at least 9, at least 10, at least 15 or more consecutive nucleotides of a target nucleic acid.
  • an ASO may be designed to ensure that it does not have a sequence (e.g., of 5 or more consecutive nucleotides) that has high complementary with an off-target nucleic acid (e.g., a wild-type C9orf72 allele).
  • a sequence e.g., of 5 or more consecutive nucleotides
  • an off-target nucleic acid e.g., a wild-type C9orf72 allele
  • Complementary refers to the capacity for precise pairing between two nucleotides. For example, if a nucleotide at a certain position of an antisense nucleic acid is capable of hydrogen bonding with a nucleotide at the corresponding position of a target nucleic acid (e.g., target RNA), then the antisense nucleic acid and target nucleic acid are considered to be complementary to each other at that position.
  • the antisense nucleic acid and target nucleic acid are complementary to each other when a sufficient number of corresponding positions in each molecule are occupied by nucleotides that can hydrogen bond with each other through their bases.
  • an antisense nucleic acid e.g., an oligonucleotide
  • an antisense nucleic acid may be at least 80% complementary to (e.g., at least 85%, 90%, 91%, 92%, 93%, 940%, 95%, 96%, 97%, 98%, 99% or 100% complementary to) the consecutive nucleotides of a target nucleic acid.
  • a complementary nucleotide sequence need not be 100% complementary to that of its target to be specifically hybridizable.
  • a complementary nucleic acid sequence for purposes of the present disclosure is specifically hybridizable when binding of the sequence to the target nucleic acid produces the desired alterations in splicing to occur and there is a sufficient degree of complementarity to avoid non-specific binding to non-target nucleic acids under conditions in which avoidance of non-specific binding is desired, e.g., under physiological conditions in the case of in vivo assays or therapeutic treatment, and in the case of in vitro assays, under conditions in which the assays are performed under suitable conditions of stringency.
  • Sequence identity including determination of sequence complementarity for nucleic acid sequences, may be determined by sequence comparison and alignment algorithms known in the art. To determine the percent identity of two nucleic acid sequences, the sequences are aligned for optimal comparison purposes (e.g., gaps can be introduced in the first sequence or second sequence for optimal alignment). The nucleotides at corresponding nucleotide positions are then compared. When a position in the first sequence is occupied by the same residue as the corresponding position in the second sequence, then the molecules are identical at that position.
  • ASOs are provided that comprise a region of complementarity that is complementary with at least 8, at least 9, at least 10, at least 11, at least 12, at least 13, at least 14, at least 15 or more contiguous nucleotides of a sequence complementary to the nucleic acid sequence of any one of SEQ ID NOs: 2-22.
  • ASOs of the disclosure have a length in a range of 5 to 40 nucleotides, 5 to 30 nucleotides, 10 to 30 nucleotides, 10 to 25 nucleotides, or 15 to 25 nucleotides.
  • oligonucleotides have a length of 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40 or more. 2T
  • antisense nucleic acids are provided in a homogeneous preparation, e.g., in which at least 85%, at least 90%, at least 95%, or at least 99% of the oligonucleotides are identical.
  • homogeneous preparations of oligonucleotides are provided in which at least 85%, at least 90%, at least 95%, or at least 99% of the oligonucleotides in the preparation are 10 to 25 nucleotides in length and comprise a region of complementarity that is complementary with at least 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19 or 20 contiguous nucleotides of any one of SEQ ID NOs: 2-22.
  • Antisense nucleic acids of the disclosure may be modified to achieve one or more desired properties, such as, for example, improved cellular uptake, improved stability, reduced immunogenicity, improved potency, improved target hybridization, susceptibility to RNAse cleavage, etc.
  • an antisense nucleic acid is modified such that when present in a cell that contains a human C90rf72 allele having a two-base pair deletion and a G4C2 repeat expansion as described herein, it is capable of hybridizing with RNA expressed from the human C90rf72 allele without inducing cleavage of the RNA by an RNase.
  • Antisense nucleic acids can be modified at a base moiety, sugar moiety and/or phosphate backbone.
  • antisense nucleic acids may have one or more modified nucleotides (e.g., a nucleotide analog) and/or one or more backbone modifications (e.g., a modified internucleotide linkage).
  • Antisense nucleic acids may have a combination of modified and unmodified nucleotides.
  • Antisense nucleic acids may also have a combination of modified and unmodified intemucleotide linkages.
  • Antisense nucleic acids may include ribonucleotides, deoxyribonucleotides, and combinations thereof.
  • modified nucleotides which can be used in antisense nucleic acids include, for example, 5-fluorouracil, 5 -bromo uracil, 5-chlorouracil, 5-iodouracil, hypoxanthine, xanthine, 4-acetylcytosine, 5-(carboxyhydroxylmethyl)uracil, 5- carboxymethylaminomethyl-2-thiouridine, 5-carboxymethylaminomethyluracil, dihydrouracil, beta-D-galactosylqueosine, inosine, N6-isopentenyladenine, 1-methylguanine, 1 -methylinosine, 2,2-dimethylguanine, 2-methyladenine, 2-methylguanine, 3-methylcytosine, 5-methylcytosine, N6-adenine, 7-methylguanine, 5-methyla
  • the ASO is a gapmer oligonucleotide.
  • a gapmer oligonucleotide has the formula 5’-A-B-C-3', wherein B is a central segment of 2T nucleotides flanked by ‘A’ and ‘C’ segments.
  • the central ‘B’ segment comprises contiguous deoxynucleotides.
  • the central segment may comprise 6-15 contiguous deoxynucleotides (e.g., 6, 7, 8, 9, 10, 11, 12, 13, 14, or 15 contiguous deoxynucleotides).
  • the ‘A’ and/or ‘C’ flanking segments comprise contiguous ribonucleotides.
  • the flanking segments may comprise 3-10 contiguous ribonucleotides (e.g., 3, 4, 5, 6, 7, 8, 9, or 10 contiguous ribonucleotides).
  • the central segment is capable of recruiting an RNAse (e.g., RNAse H).
  • the gapmer binds to the target nucleic acid to recruit an RNAse.
  • the flanking segments comprise modified nucleotides.
  • each of the nucleotides in a flanking segment are modifed nucleotides (e.g., modified ribonucleotides).
  • a modified nucleotide is a 2’ methoxy ethyl modified nucleotide, a 2’ o-methyl modified nucleotide, or a locked nucleic acid.
  • the two flanking segments comprise the same number of nucleotides. In other embodiments, the two flanking segments comprise different numbers of nucleotides.
  • a gapmer is a 5-10-5 gapmer (e.g., comprising a central segment of ten 2’ deoxynucleotides flanked by five ribonucleotides, e.g., five 2’ methoxyethyl (MOE) ribonucleotides).
  • a gapmer is a 4-8-4 gapmer (e.g., comprising a central segment of eight 2’ deoxynucleotides flanked by four nucleotides, e.g., four locked nucleic acid (LN A) nucleotides).
  • LN A locked nucleic acid
  • a modified nucleotide is a 2’-modified nucleotide.
  • the 2’-modified nucleotide may be a 2’-deoxy, 2’-fluoro, 2’-O-methyl, 2’-O- methoxyethyl, 2’-amino and 2’ -aminoalkoxy modified nucleotides.
  • the 2’-modified nucleotide comprises a 2’-O-4’-C methylene bridge, such as a locked nucleic acid (LNA) nucleotide.
  • LNA locked nucleic acid
  • the 2'-hydroxyl group is linked to the 3' or 4' carbon atom of the sugar ring thereby forming a bicyclic sugar moiety.
  • the linkage may be a methelyne ( — CH2 — ) n group bridging the 2' oxygen atom and the 3' or 4' carbon atom wherein n is 1 or 2.
  • Antisense nucleic acids may include combinations of LNA nucleotides and unmodified nucleotides.
  • Antisense nucleic acids may include combinations of LNA and RNA nucleotides.
  • Antisense nucleic acids may include combinations of LNA and DNA nucleotides.
  • a further preferred oligonucleotide modification includes Locked Nucleic Acids (LNAs) in which the 2 '-hydroxyl group is linked to the 3' or 4' carbon atom of the sugar ring thereby forming a bicyclic sugar moiety.
  • LNAs Locked Nucleic Acids
  • Antisense nucleotide acids may also include nucleobase-modified nucleotides, e.g. , nucleotides containing a non-naturally occurring nucleobase instead of a naturally occurring nucleobase.
  • Bases may be modified to block the activity of adenosine deaminase, for example. 2T
  • modified nucleobases include, but are not limited to, uridine and/or cytidine modified at the 5-position, e.g., 5-(2-amino)propyl uridine, 5-bromo uridine; adenosine and/or guanosines modified at the 8 position, e.g., 8-bromo guanosine; deaza nucleotides, e.g., 7-deaza- adenosine; O- and N-alkylated nucleotides, e.g., N6-methyl adenosine are suitable. It should be noted that the above modifications may be combined.
  • an oligonucleotide e.g., an oligonucleotide of 20 nucleotides in length
  • an oligonucleotide may contain 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19 or 20 modified nucleotides.
  • a modified oligonucleotide will contain as few modified nucleotides as are necessary to achieve a desired level of in vivo stability and/or bioaccessibility or other desired property.
  • antisense nucleic acids may include nonionic DNA analogs, such as alkyl- and aryl-phosphates (in which the charged phosphonate oxygen is replaced by an alkyl or aryl group), phosphodiester and alkylphosphotriesters, in which the charged oxygen moiety is alkylated.
  • Nucleic acids which contain a diol, such as tetraethyleneglycol or hexaethyleneglycol, at either or both termini have also been shown to be substantially resistant to nuclease degradation and may be used herein.
  • antisense nucleic acids may include at least one lipophilic substituted nucleotide analog and/or a pyrimidine-purine dinucleotide.
  • antisense nucleic acids may have one or two accessible 5' ends. It is possible to create modified oligonucleotides having two such 5' ends, for instance, by attaching two oligonucleotides through a 3 '-3' linkage to generate an oligonucleotide having one or two accessible 5' ends.
  • the 3'3'-linkage may be a phosphodiester, phosphorothioate or any other modified internucleoside bridge.
  • 3 '3 '-linked oligonucleotides where the linkage between the 3' terminal nucleosides is not a phosphodiester, phosphorothioate or other modified bridge, can be prepared using an additional spacer, such as tri- or tetra-ethylenglycol phosphate moiety.
  • a phosphodiester internucleotide linkage of an antisense nucleic acid can be replaced with a modified linkage.
  • the modified linkage may be selected from, for example, phosphorothioate, phosphorodithioate, NRlR2-phosphoramidate, boranophosphate, a- hydroxybenzyl phosphonate, phosphate-(Cl-C21) — O-alkyl ester, phosphate-[(C6-C12)aryl- (C1-C21) — O-alkyl]ester, (Cl-C8)alkylphosphonate and/or (C6-C12)arylphosphonate bridges, and (C7-C12)-a-hydroxymethyl-aryl.
  • a phosphate backbone of the antisense nucleic acid can be modified to generate peptide nucleic acid molecules.
  • peptide nucleic acids or “PNAs” 2T refer to nucleic acid mimics, e.g., DNA mimics, in which the deoxyribose phosphate backbone is replaced by a pseudopeptide backbone and only the four natural nucleobases are retained.
  • the neutral backbone of PNAs has been shown to allow for specific hybridization to DNA and RNA under conditions of low ionic strength.
  • the synthesis of PNA oligomers can be performed using standard solid phase peptide synthesis protocols, for example.
  • Antisense nucleic acids can also be formulated as morpholino oligonucleotides.
  • the riboside moiety of each subunit of an oligonucleotide of the oligonucleotide reagent is converted to a morpholine moiety.
  • Morpholinos may also be modified, for example, as a peptide conjugated morpholino, a phosphorodiamidate morpholino, and the like.
  • the antisense nucleic acid can be linked to functional groups such as peptides (e.g., for targeting host cell receptors in vivo), or agents facilitating transport across the cell membrane or the blood-brain barrier.
  • Oligonucleotide reagents of the disclosure also may be modified with chemical moieties (e.g., cholesterol) that improve the in vivo pharmacological properties of the oligonucleotide reagents.
  • Methods are provided herein for inhibiting the expression of genes that are associated with FTD and/or ALS, such as C90rf72.
  • methods are provided for inhibiting the expression of C90rf72 (e.g., mutated C90rf72 allele comprising a two-base pair deletion and a G4C2 repeat expansion, e.g., mutated C90rf72 allele comprising a nucleic acid sequence of SEQ ID NO: 2 and a G4C2 repeat expansion) in a cell that involve delivering to the cell an inhibitory nucleic acid (e.g., an ASO) that targets a C90rf72 allele.
  • the cell may be in vitro or in vivo.
  • the cell may be a human cell, such as a cell from a subject having one or more symptoms of ALS and/or FTD, or from a subject having or suspected of having ALS and/or (FTD.
  • methods are provided for inhibiting the expression of a mutated C90rf72 allele (e.g., comprising a two-base pair deletion and a G4C2 repeat expansion) in a cell that involve administering to the central nervous system (CNS) of the subject an ASO that targets an RNA encoded by the mutated C90rf72 allele, wherein the ASO is complementary to a mutated C90rf72 allele comprising a two-base pair C9-deletion (e.g., mutated C90rf72 allele comprising a nucleic acid sequence of SEQ ID NO: 2 and a G4C2 repeat expansion).
  • CNS central nervous system
  • methods are provided for inhibiting C90rf72 expression in the CNS of a subject.
  • the methods involve administering to the CNS of the subject an inhibitory nucleic acid that targets both pre-mRNA and mRNA encoded by a 2T
  • the inhibitory nucleic acid comprises a sequence complementary to a segment of the mutated C90rf72 sequence comprising the nucleic acid sequence of any one of SEQ ID NOs: 2-22.
  • an effective amount of any of the inhibitory nucleic acids e.g., any of the ASOs disclosed herein.
  • the “effective amount” of an inhibitory nucleic acid refers to an amount sufficient to elicit the desired biological response.
  • the ASO reduces levels of C90rf72 expression in the cell by at least 10%.
  • an effective amount is the maximum amount that is considered to be safe for the patient. In some embodiments, an effective amount is the lowest possible concentration that provides maximum efficacy.
  • an effective amount may be 1-10, 1-50, 5-50, 10-75, 50-100 mg/kg, or more, depending on the factors described herein and known to a person of skill in the art.
  • the effective amount refers to the amount effective for direct administration of an inhibitory nucleic acid (e.g., an ASO) to a subject.
  • an inhibitory nucleic acid e.g., an ASO
  • the effective amount of the inhibitory nucleic acid (e.g., an ASO) of the invention varies depending on such factors as the desired biological endpoint, the pharmacokinetics of the expression products, the condition being treated, the mode of administration, and the subject.
  • the inhibitory nucleic acid e.g., an ASO
  • At least one clinical outcome parameter or biomarker e.g., intranuclear G4C2 RNA foci, RAN- protein expression, and the like
  • the clinical outcome parameter or biomarker evaluated after administration of the inhibitory nucleic acid is compared with the clinical outcome parameter or biomarker determined at a time prior to administration of the inhibitory nucleic acid (e.g., ASO) to determine effectiveness of the inhibitory nucleic acid (e.g., ASO).
  • an improvement in the clinical outcome parameter or biomarker after administration of the inhibitory nucleic acid indicates effectiveness of the inhibitory nucleic acid (e.g., ASO).
  • Any appropriate clinical outcome parameter or biomarker may be used.
  • the clinical outcome parameter or biomarker is indicative of the one or more symptoms of an FTD or ALS.
  • the clinical outcome parameter or biomarker may be selected from the group consisting of: intranuclear G4C2 RNA foci, C90rf72 expression, memory loss, and presence or absence of movement disorders such as unsteadiness, rigidity, slowness, twitches, muscle 2T weakness or difficulty swallowing, speech and language difficulties, twitching (fasciculation) and cramping of muscles, including those in the hands and feet.
  • the disclosure provides methods for treating a subject having amyotrophic lateral sclerosis (ALS) or at risk of having ALS. In some aspects, the disclosure provides methods for treating a subject having frontotemporal dementia (FTD) or at risk of having FTD.
  • a subject can be a human, non-human primate, rat, mouse, cat, dog, or other mammal.
  • treatment refers to therapeutic treatment and prophylactic or preventative manipulations.
  • the terms further include ameliorating existing symptoms, preventing additional symptoms, ameliorating or preventing the underlying causes of symptoms, preventing or reversing causes of symptoms, for example, symptoms associated with ALS and/or FTD.
  • the terms denote that a beneficial result has been conferred on a subject having ALS and/or FTD, or with the potential to develop such a disorder.
  • treatment may include the application or administration of an inhibitory nucleic acid (e.g., a therapeutic ASO or a pharmaceutical composition comprising an ASO) to a subject, or an isolated tissue or cell line from a subject, who may have a disease, a symptom of disease or a predisposition toward a disease, with the purpose to cure, heal, alleviate, relieve, alter, remedy, ameliorate, improve or affect the disease, the symptoms of disease or the predisposition toward disease.
  • an inhibitory nucleic acid e.g., a therapeutic ASO or a pharmaceutical composition comprising an ASO
  • inhibitory nucleic acid e.g., ASO
  • the inhibitory nucleic acid may be an antisense oligonucleotide (e.g. , of 10 to 25 nucleotides in length) comprising a sequence complementary to a nucleic acid sequence of any one of SEQ ID NOs: 2-22, specifically complementary with at least 8 contiguous nucleotides of any one of SEQ ID NOs: 2-22.
  • antisense nucleic acids may be administered by any suitable route.
  • an effective amount of the antisense nucleic acid and/or other therapeutic agent can be administered to a subject by any mode that delivers the agent to the desired tissue, e.g., neuronal tissue.
  • agents e.g., ASOs
  • suitable routes of administration include but are not limited to oral, parenteral, intravenous, intraperitoneal, intranasal, sublingual, intratracheal, inhalation, subcutaneous, ocular, vaginal, and rectal.
  • Systemic routes include oral and parenteral.
  • Several types of devices are regularly used for administration by inhalation. These types of devices 2T include metered dose inhalers (MDI), breath-actuated MDI, dry powder inhaler (DPI), spacer/holding chambers in combination with MDI, and nebulizers.
  • MDI metered dose inhalers
  • DPI dry powder inhaler
  • the agents can be formulated readily by combining the active compound(s) with pharmaceutically acceptable carriers well known in the art.
  • Such carriers enable the agents of the disclosure to be formulated as tablets, pills, dragees, capsules, liquids, gels, syrups, slurries, suspensions and the like, for oral ingestion by a subject to be treated.
  • Pharmaceutical preparations for oral use can be obtained as solid excipient, optionally grinding a resulting mixture, and processing the mixture of granules, after adding suitable auxiliaries, if desired, to obtain tablets or dragee cores.
  • Suitable excipients are, in particular, fillers such as sugars, including lactose, sucrose, mannitol, or sorbitol; cellulose preparations such as, for example, maize starch, wheat starch, rice starch, potato starch, gelatin, gum tragacanth, methyl cellulose, hydroxypropylmethyl cellulose, sodium carboxymethylcellulose, and/or polyvinylpyrrolidone (PVP).
  • disintegrating agents may be added, such as the cross-linked polyvinyl pyrrolidone, agar, or alginic acid or a salt thereof such as sodium alginate.
  • oral formulations may also be formulated in saline or buffers for neutralizing internal acid conditions or may be administered without any carriers.
  • Delivery of certain inhibitory nucleic acids (e.g., ASOs) to a subject may be, for example, by administration into the bloodstream of the subject. Administration into the bloodstream may be by injection into a vein, an artery, or any other vascular conduit. Moreover, in certain instances, it may be desirable to deliver the inhibitory nucleic acids (e.g., ASOs) to brain tissue, meninges, neuronal cells, glial cells, astrocytes, oligodendrocytes, cereobro spinal fluid (CSF), interstitial spaces and the like.
  • ASOs inhibitory nucleic acids
  • inhibitory nucleic acids may be delivered directly to the spinal cord or brain (e.g., prefrontal cortex) by injection into the ventricular region, as well as to the striatum (e.g., the caudate nucleus or putamen of the striatum), and neuromuscular junction, or cerebellar lobule, with a needle, catheter or related device, using neurosurgical techniques known in the art, such as by stereotactic injection (see, e.g., Stein et al., J Virol 73:3424-3429, 1999; Davidson et al., PNAS 97:3428-3432, 2000; Davidson et al., Nat. Genet. 3:219-223, 1993; and Alisky and Davidson, Hum. Gene Ther. 11:2315-2329, 2000).
  • ASOs inhibitory nucleic acids
  • compositions that can be used orally include push fit capsules made of gelatin, as well as soft, sealed capsules made of gelatin and a plasticizer, such as glycerol or sorbitol.
  • the push fit capsules can contain the active ingredients in admixture with filler such as lactose, binders such as starches, and/or lubricants such as talc or magnesium stearate and, optionally, stabilizers.
  • the active agents may be dissolved or suspended in suitable liquids, such as fatty oils, liquid paraffin, or liquid polyethylene glycols. 2T
  • microspheres formulated for oral administration may also be used. Such microspheres have been well defined in the art. Formulations for oral administration are typically in dosages suitable for such administration.
  • compositions may take the form of tablets or lozenges formulated in conventional manner.
  • agents for use according to the present disclosure may be conveniently delivered in the form of an aerosol spray presentation from pressurized packs or a nebulizer, with the use of a suitable propellant, e.g., dichlorodifluoromethane, trichlorofluoromethane, dichloro tetrafluoroethane, carbon dioxide or other suitable gas.
  • a suitable propellant e.g., dichlorodifluoromethane, trichlorofluoromethane, dichloro tetrafluoroethane, carbon dioxide or other suitable gas.
  • the dosage unit may be determined by providing a valve to deliver a metered amount.
  • Capsules and cartridges of gelatin for example, for use in an inhaler or insufflator may be formulated containing a powder mix of the compound and a suitable powder base such as lactose or starch.
  • the agents when it is desirable to deliver them systemically, may be formulated for parenteral administration by injection, for example, by bolus injection or continuous infusion.
  • Formulations for injection may be presented in unit dosage form, for example, in ampoules or in multi-dose containers, with an added preservative.
  • the compositions may take such forms as suspensions, solutions or emulsions in oily or aqueous vehicles, and may contain formulatory agents such as suspending, stabilizing and/or dispersing agents.
  • compositions for parenteral administration include aqueous solutions of agents (e.g., ASOs) in water-soluble form. Additionally, suspensions of agents may be prepared as appropriate oily injection suspensions. Suitable lipophilic solvents or vehicles include fatty oils such as sesame oil, or synthetic fatty acid esters, such as ethyl oleate or triglycerides, or liposomes. Aqueous injection suspensions may contain substances that increase the viscosity of the suspension, such as sodium carboxymethyl cellulose, sorbitol, or dextran. Optionally, the suspension may also contain suitable stabilizers or agents that increase the solubility of the agents to allow for the preparation of highly concentrated solutions.
  • agents e.g., ASOs
  • suspensions of agents may be prepared as appropriate oily injection suspensions.
  • Suitable lipophilic solvents or vehicles include fatty oils such as sesame oil, or synthetic fatty acid esters, such as ethyl oleate or triglycerides, or lip
  • agents may be in powder form for constitution with a suitable vehicle, for example, sterile pyrogen-free water, before use.
  • Agents e.g., ASOs
  • Other delivery systems can include time-release, delayed release or sustained release delivery systems. Such systems can avoid repeated administrations of the agents (e.g., ASOs), increasing convenience to the subject and the physician.
  • agents e.g., ASOs
  • release delivery systems include polymer base systems such as poly(lactide glycolide), 2T copolyoxalates, polycaprolactones, polyesteramides, polyorthoesters, polyhydroxybutyric acid, and polyanhydrides.
  • Delivery systems also include non-polymer systems that are: lipids including sterols such as cholesterol, cholesterol esters and fatty acids or neutral fats such as mono, di, and tri glycerides; hydrogel release systems; silastic systems; peptide-based systems; wax coatings; compressed tablets using conventional binders and excipients; partially fused implants; and others disclosed herein.
  • compositions are provided that comprise an agent (e.g., an ASO or vector comprising the same) and a carrier.
  • carrier refers to an organic or inorganic ingredient, natural or synthetic, with which the active ingredient is combined to facilitate an intended use.
  • pharmaceutical compositions are provided that comprise an antisense nucleic acid and a pharmaceutically- acceptable carrier.
  • pharmaceutically acceptable carrier refers to a carrier that is suitable for pharmaceutical administration.
  • pharmaceutically-acceptable carrier includes compatible solid or liquid fillers, diluents or encapsulating substances that are suitable for administration to a human or other vertebrate animal.
  • compositions also are capable of being commingled with the agents of the present disclosure, and with each other, in a manner such that there is no interaction that would substantially impair the desired pharmaceutical efficiency.
  • Pharmaceutical compositions may include solvents, dispersion media, coatings, antibacterial and antifungal agents, isotonic and absorption delaying agents, and other suitable components compatible with pharmaceutical administration. Supplementary active agents can also be incorporated into the compositions. Active ingredients (e.g., ASOs) may be admixed or compounded with any conventional, pharmaceutically acceptable carrier or excipient.
  • Pharmaceutical compositions are generally sterile and prepared using aseptic technique. A sterile phosphate-buffered saline is one example of a pharmaceutically acceptable carrier.
  • compositions also may comprise suitable solid or gel phase carriers or excipients.
  • suitable solid or gel phase carriers or excipients include but are not limited to calcium carbonate, calcium phosphate, various sugars, starches, cellulose derivatives, gelatin, and polymers such as polyethylene glycols.
  • Inhibitory nucleic acids may be administered per se (neat) or in the form of a pharmaceutically acceptable salt.
  • the salts are generally pharmaceutically acceptable, but non-pharmaceutically acceptable salts may conveniently be used to prepare pharmaceutically acceptable salts thereof.
  • Such salts include, but are not limited 2T to, those prepared from the following acids: hydrochloric, hydrobromic, sulphuric, nitric, phosphoric, maleic, acetic, salicylic, p-toluene sulphonic, tartaric, citric, methane sulphonic, formic, malonic, succinic, naphthalene-2-sulphonic, and benzene sulphonic.
  • such salts can be prepared as alkaline metal or alkaline earth salts, such as sodium, potassium or calcium salts of the carboxylic acid group.
  • Exemplary buffering agents include: acetic acid and a salt (1-2% w/v); citric acid and a salt (1-3% w/v); boric acid and a salt (0.5-2.5% w/v); and phosphoric acid and a salt (0.8- 2% w/v).
  • Suitable preservatives include benzalkonium chloride (0.003-0.03% w/v); chlorobutanol (0.3-0.9% w/v); parabens (0.01-0.25% w/v) and thimerosal (0.004-0.02% w/v).
  • compositions may conveniently be presented in unit dosage form and may be prepared by any of the methods well known in the art of pharmacy. All methods include the step of bringing the agents into association with a carrier that constitutes one or more accessory ingredients. In general, the compositions are prepared by uniformly and intimately bringing the agents into association with a liquid carrier, a finely divided solid carrier, or both, and then, if necessary, shaping the product. Liquid dose units are vials or ampoules. Solid dose units are tablets, capsules and suppositories.
  • An effective amount, also referred to as a therapeutically effective amount, of an ASO capable of inhibiting a mutated C90rf72 allele comprising a C9-deletion (e.g., a mutated C90rf72 allele comprising SEQ ID NO: 2 and a G4C2 repeat expansion) is expressed is an amount sufficient to ameliorate at least one adverse effect associated with expression, or reduced expression, of the gene in a cell or in an individual in need of such modulation.
  • the therapeutically effective amount to be included in pharmaceutical compositions may be selected based upon several factors, for example, the type, size and condition of the patient to be treated, the intended mode of administration, the capacity of the patient to incorporate the intended dosage form, and the like.
  • inhibitory nucleic acids may be prepared in a colloidal dispersion system.
  • Colloidal dispersion systems include lipid-based systems including oil-in-water emulsions, micelles, mixed micelles, and liposomes.
  • An example of a colloidal system that may be used in methods provided herein is a liposome.
  • Liposomes are artificial membrane vessels that are useful for delivering antisense nucleic acids in vivo or in vitro. It has been shown that large unilamellar vesicles can encapsulate large macromolecules. Nucleic acids and other components (e.g., viral vectors) can be encapsulated within the aqueous interior and be delivered to cells in a biologically active form.
  • Liposomes may be targeted to a particular tissue by coupling the liposome to a specific ligand such as a monoclonal antibody, sugar, glycolipid, or protein.
  • Ligands which may be useful for targeting a liposome to, for example, a smooth muscle 2T cell or skeletal muscle cell include, but are not limited to: intact or fragments of molecules that interact with muscle cell specific receptors and molecules, such as antibodies, which interact with the cell surface markers.
  • Lipid formulations for transfection are commercially available from QIAGEN, for example, as EFFECTENETM (a non-liposomal lipid with a special DNA condensing enhancer) and SUPERFECTTM (a dendrimeric technology).
  • Liposomes are commercially available from Invitrogen, Life Technologies, for example, as LIPOFECTINTM, which is formed of cationic lipids such as N-[l-(2, 3 dioley loxy)-propyl]-N, N, N- trimethylammonium chloride (DOTMA) and dioleoyl phophotidylethanolamine (DOPE), as well as other lipid-based reagents including Lipofectamine and Oligofectamine.
  • Certain cationic lipids, including in particular N-[l-(2, 3 dioleoyloxy)-propyl]-N,N,N-trimethylammonium methyl-sulfate (DOTAP) may be advantageous when combined with the ASO analogs of the disclosure.
  • inhibitory nucleic acids may be formulated with a biocompatible microparticle or implant that is suitable for implantation or administration to a recipient.
  • Bioerodible implants may include a biodegradable polymeric matrix, for example, for containing an exogenous expression construct engineered to express an antisense nucleic acid under the control of an appropriate promoter.
  • the polymeric matrix can be used to achieve sustained release of the therapeutic agent in the subject.
  • a polymeric matrix may be in the form of a microparticle such as a microsphere, in which an antisense nucleic acid and/or other therapeutic agent is dispersed throughout a solid polymeric matrix, or a microcapsule, in which antisense nucleic acid and/or other therapeutic agent is stored in the core of a polymeric shell.
  • Other forms of the polymeric matrix for containing a therapeutic agent include films, coatings, gels, implants, and stents.
  • the matrix composition also can be selected not to degrade, but rather, to release by diffusion over an extended period of time.
  • inhibitory nucleic acids are administered to the subject via an implant while the other therapeutic agent is administered.
  • Both non-biodegradable and biodegradable polymeric matrices can be used to deliver ASOs and/or the other therapeutic agent to a subject.
  • Biodegradable matrices are preferred.
  • Such polymers may be natural or synthetic polymers. The polymer is selected based on the period of time over which release is desired, generally in the order of a few hours to a year or longer. Typically, release over a period ranging from between a few hours and three to twelve months may be used.
  • a polymer may be in the form of a hydrogel, for example, a hydrogel that can absorb up to about 90% of its weight in water and which is optionally cross-linked with multi-valent ions or other components, for example, polymers. 2T
  • compositions that can be used to facilitate uptake of a nucleic acid include calcium phosphate and other chemical mediators of intracellular transport, microinjection compositions, electroporation and homologous recombination compositions (e.g., for integrating a nucleic acid into a preselected location within the target cell chromosome).
  • the agents may also be formulated as a depot preparation.
  • Such long-acting formulations may be formulated with suitable polymeric or hydrophobic materials (for example as an emulsion in an acceptable oil) or ion exchange resins, or as sparingly soluble derivatives, for example, as a sparingly soluble salt.
  • liquid or solid pharmaceutical preparation forms are, for example, aqueous or saline solutions for inhalation, microencapsulated, encochleated, coated onto microscopic gold particles, contained in liposomes, nebulized, aerosols, pellets for implantation into the skin, or dried onto a sharp object to be scratched into the skin.
  • the pharmaceutical compositions also include granules, powders, tablets, coated tablets, (micro)capsules, suppositories, syrups, emulsions, suspensions, creams, drops or preparations with protracted release of active compounds, in whose preparation excipients and additives and/or auxiliaries such as disintegrants, binders, coating agents, swelling agents, lubricants, flavorings, sweeteners or solubilizers are customarily used as described above.
  • Suitable carriers may be readily selected by one of skill in the art in view of the indication for which the inhibitory nucleic acid (e.g., ASO) is directed.
  • one suitable carrier includes saline, which may be formulated with a variety of buffering solutions (e.g., phosphate buffered saline).
  • buffering solutions e.g., phosphate buffered saline.
  • Other exemplary carriers include sterile saline, lactose, sucrose, calcium phosphate, gelatin, dextran, agar, pectin, peanut oil, sesame oil, and water. Still others will be apparent to the skilled artisan.
  • compositions of the invention may contain, in addition to the ASO and carrier(s), other conventional pharmaceutical ingredients, such as preservatives, or chemical stabilizers.
  • suitable exemplary preservatives include chlorobutanol, potassium sorbate, sorbic acid, sulfur dioxide, propyl gallate, the parabens, ethyl vanillin, glycerin, phenol, and parachlorophenol.
  • Suitable chemical stabilizers include gelatin and albumin.
  • compositions are suitable for use in a variety of drug delivery systems.
  • Delivery vehicles such as liposomes, nanocapsules, microparticles, microspheres, lipid particles, vesicles, and the like, may be used for the introduction of the compositions of the present invention into suitable host cells.
  • liposomes are generally known to those of skill in the art. Recently, liposomes were developed with improved serum stability and circulation half-times (U.S. Pat. No. 5,741,516). Further, various methods of liposome and liposome like preparations 2T as potential drug carriers have been described (U.S. Pat. Nos. 5,567,434; 5,552,157; 5,565,213; 5,738,868 and 5,795,587).
  • Liposomes have been used successfully with a number of cell types that are normally resistant to transfection by other procedures. In addition, liposomes are free of the DNA length constraints that are typical of viral-based delivery systems. Liposomes have been used effectively to introduce genes, drugs, radiotherapeutic agents, viruses, transcription factors and allosteric effectors into a variety of cultured cell lines and animals. In addition, several successful clinical trials examining the effectiveness of liposome-mediated drug delivery have been completed.
  • Liposomes are formed from phospholipids that are dispersed in an aqueous medium and spontaneously form multilamellar concentric bilayer vesicles (also termed multilamellar vesicles (MLVs).
  • MLVs generally have diameters of from 25 nm to 4 pm. Sonication of MLVs results in the formation of small unilamellar vesicles (SUVs) with diameters in the range of 200 to 500 angstroms, containing an aqueous solution in the core.
  • SUVs small unilamellar vesicles
  • Nanocapsule formulations of the inhibitory nucleic acid may be used.
  • Nanocapsules can generally entrap substances in a stable and reproducible way.
  • ultrafine particles sized around 0.1 pm
  • Biodegradable polyalkyl-cyanoacrylate nanoparticles that meet these requirements are contemplated for use.
  • the following techniques are also contemplated as alternative methods of delivering the inhibitory nucleic acid (e.g., ASO) compositions to a host.
  • Sonophoresis e.g., ultrasound
  • U.S. Pat. No. 5,656,016 Sonophoresis (e.g., ultrasound) has been used and described in U.S. Pat. No. 5,656,016 as a device for enhancing the rate and efficacy of drug permeation into and through the circulatory system.
  • Other drug delivery alternatives contemplated are intraosseous injection (U.S. Pat. No. 5,779,708), microchip devices (U.S. Pat. No. 5,797,898), ophthalmic formulations, transdermal matrices (U.S. Pat. Nos. 5,770,219 and 5,783,208) and feedback-controlled delivery (U.S. Pat. No. 5,697,899).
  • kits may include one or more containers housing the components of the invention and instructions for use.
  • kits may include one or more agents described herein, along with instructions describing the intended application and the proper use of these agents.
  • 2T agents in a kit may be in a pharmaceutical formulation and dosage suitable for a particular application and for a method of administration of the agents.
  • Kits for research purposes may contain the components in appropriate concentrations or quantities for running various experiments.
  • the kit may be designed to facilitate use of the methods described herein by researchers and can take many forms.
  • Each of the compositions of the kit may be provided in liquid form (e.g., in solution), or in solid form, (e.g., a dry powder).
  • some of the compositions may be constitutable or otherwise processable (e.g., to an active form), for example, by the addition of a suitable solvent or other species (for example, water or a cell culture medium), which may or may not be provided with the kit.
  • a suitable solvent or other species for example, water or a cell culture medium
  • “instructions” can define a component of instruction and/or promotion, and typically involve written instructions on or associated with packaging of the invention.
  • Instructions also can include any oral or electronic instructions provided in any manner such that a user will clearly recognize that the instructions are to be associated with the kit, for example, audiovisual (e.g., videotape, DVD, and the like.), Internet, and/or web-based communications, and the like.
  • the written instructions may be in a form prescribed by a governmental agency regulating the manufacture, use or sale of pharmaceuticals or biological products, which instructions can also reflects approval by the agency of manufacture, use or sale for animal administration.
  • the kit may contain any one or more of the components described herein in one or more containers.
  • the kit may include instructions for mixing one or more components of the kit and/or isolating and mixing a sample and applying to a subject.
  • the kit may include a container housing agents described herein.
  • the agents may be in the form of a liquid, gel or solid (powder).
  • the agents may be prepared sterilely, packaged in syringe and shipped refrigerated. Alternatively it may be housed in a vial or other container for storage. A second container may have other agents prepared sterilely.
  • the kit may include the active agents premixed and shipped in a syringe, vial, tube, or other container.
  • the kit may have one or more or all of the components required to administer the agents to a subject, such as a syringe, topical application devices, or IV needle tubing and bag.
  • Variants of C90rf72 that could be used as targets for allele specific antisense technologies were identified using whole genome sequencing (WGS) data from 204 C90rf72 2T patients that were reported to have a repeat expansion.
  • WGS whole genome sequencing
  • indel insertion/deletion
  • SNPs single nucleotide polymorphisms
  • the RS number for the two indels were RS 142843265 and RS34620383.
  • Variant alleles in linkage disequilibrium (LD) were consistently present on the same chromosome (travelled together).
  • a two base pair deletion in C9orf72 (C9-deletion or C9-del), as shown in FIG. 1, was identified as being in linkage disequilibrium with G4C2 repeat expansions.
  • the heterozygosity frequency of the C9-deletion indel was 79% of C90rf72 patients.
  • the RS number for the ten SNPS were: rs2453565, rs700828, rs774356, rs774357, rs774359, rs2453554, rs2484319, rs2453555, rs2492816, and rs3849945.
  • Antisense oligonucleotides (ASOs) for targeting mutated C90rf72 genes comprising the C9-deletion were designed using 1-base pair tiling over the indel site (see, bottom of FIG. 1).
  • ASOs were synthesized using two different chemistries - (1) 5-10-5 MOE gapmer technology (central segment of ten 2’ deoxynucleotides flanked by five 2’ methoxy ethyl (MOE) ribonucleotides); and (2) 4-8/9-4 LNA gapmer technology (central segment of eight or nine 2’ deoxynucleotides flanked by four locked nucleic acid (LNA) nucleotides).
  • LNA locked nucleic acid
  • an ASO comprising a sequence that was complementary to SEQ ID NO: 12 or 13 resulted in approximately 80% inhibition of C90rf72 expression in C9- del/C9-del cells, and approximately 5-10% inhibition of C90rf72 expression in wild-type cells.
  • a dual luciferase assay was also performed to evaluate the allele-specific ASOs of this Example.
  • the dual luciferase assay utilized two luciferase genes, wherein the first gene comprised a portion of the C90rf72 gene at its 3’ end. Binding of an ASO to C90rf72 gene at the 3’ end of the first luciferase gene resulted in lowered expression from the first luciferase gene.
  • the second luciferase gene functioned as an internal control for normalization purposes.
  • Candidate target regions were cloned into luciferase expression vectors 2T
  • FIG. 4A Several tested MOE gapmer ASOs (FIG. 4A) as provided in Table 1 were shown to be effective in reducing gene expression in this luciferase assay in an allele- specific manner (i.e., greater reduction in expression of the mutant C9-del allele relative to the normal allele).
  • MOE gapmer of SEQ ID NO: 30 ASO 8
  • FIG. 4C It was further shown that the MOE gapmer of SEQ ID NO: 30 (ASO 8) was capable of reducing gene expression in a dosedependent manner
  • LNA gapmer of SEQ ID NO: 52 (LNA 10) was capable of reducing gene expression in a dose-dependent manner, while LNA gamper of SEQ ID NO: 51 (LNA9) had a robust knockdown ability even at the lowest concentrations tested(FIG. 6C).
  • a qRT-PCR assay was also used to directly measure allelespecific C90rf72 knockdown. Fibroblasts were plated in 24 well plates, grown overnight, then treated with lOOnM ASOs for 48hrs. RNA was isolated from the cells, converted to cDNA, and used an input material for qRT-PCR. 100 ng of each sample was used to probe RPP30 (Ctrl) and C90rf72. Each sample was run in duplicate and C9 levels were normalized to RPP30 and nontreated controls. 2T
  • Example 4 Location of C9 deletion variant and a second variant within the C90rf72 gene
  • Example 5 Experiment confirming reduction of individual allelic expression in cells
  • Example 6 Experiment showing allele specific ASO treatment of patient cells partially rescues a patient phenotype
  • PS Phosphorothioate
  • RNA-Seq is used to establish level of rescue of gene expression.
  • BAC mouse models comprising a mutated C90rf72 gene (homozygous and/or heterozygous populations for the C9-deletion) are generated to evaluate ASOs in vivo. ASOs are then dosed into mice using an intravenous administration.
  • AATTGCATGAGTCTTAACGATACAACATAAGACTTAGAAGAAATATTGTGTGGACC TGGGCCTACACCCCAGACAGATACCTCAGGGGTACATATGCTCCTTCTGTTACAG CTACTTCTAGGGAAAGGTTCGAGAAGTAGTACCTTAAAGAACATATCAGAGACAAT TTTTTTTATTTTTACTATGAACAAGTTATCCAAAATTTATTCTGGGCAAACAGAAAA AAAAAGGGAGCAAATATTAATTTGTAGATGCAATTACTATTTTCCTTTGTTTACTGA TTTAACTCTTTGGGTTTAAG
  • C90rf72 allele comprising a two-base pair deletion (C9-deletion) (SEQ ID NO: 2)
  • AATTGCATGAGTCTTAACGATACAACATAAGACTTAGAAGAAATATTGTGTGGACC TGGGCCTACACCCCAGACAGATACCTCAGGGGTACATATGCTCCTTCTGTTACAG CTACTTCTAGGGAAAGGTTCGAGAAGTAGTACCTTAAAACATATCAGAGACAATTT TTTTTATTTTTACTATGAACAAGTTATCCAAAATTTATTCTGGGCAAACAGAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA
  • Antisense oligonucleotide target (Indel +10) (SEQ ID NO: 3)
  • Antisense oligonucleotide target (Indel +9) (SEQ ID NO: 4)
  • Antisense oligonucleotide target (Indel +8) (SEQ ID NO: 5)
  • Antisense oligonucleotide target (Indel +7) (SEQ ID NO: 6)
  • Antisense oligonucleotide target (Indel +6) (SEQ ID NO: 7)
  • Antisense oligonucleotide target (Indel +5) (SEQ ID NO: 8)
  • Antisense oligonucleotide target (Indel +4) (SEQ ID NO: 9)
  • Antisense oligonucleotide target (Indel +3) (SEQ ID NO: 10)
  • Antisense oligonucleotide target (Indel +2) (SEQ ID NO: 11)
  • Antisense oligonucleotide target (Indel +1) (SEQ ID NO: 12)
  • Antisense oligonucleotide target (Indel +0) (SEQ ID NO: 13)
  • Antisense oligonucleotide target (Indel -1) (SEQ ID NO: 14)
  • Antisense oligonucleotide target (Indel -2) (SEQ ID NO: 15)
  • Antisense oligonucleotide target (Indel -3) (SEQ ID NO: 16)
  • Antisense oligonucleotide target (Indel -4) (SEQ ID NO: 17)
  • Antisense oligonucleotide target (Indel -5) (SEQ ID NO: 18)
  • Antisense oligonucleotide target (Indel -6) (SEQ ID NO: 19)
  • Antisense oligonucleotide target (Indel -7) (SEQ ID NO: 20)
  • Antisense oligonucleotide target (Indel -8) (SEQ ID NO: 21)
  • Antisense oligonucleotide target (Indel -9) (SEQ ID NO: 22)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Selon certains modes de réalisation, les oligonucléotides antisens décrits dans la présente invention ciblent une séquence C90rf72 comprenant une délétion de deux paires de bases et des expansions répétées G4C2 ; et leurs procédés d'utilisation pour inhiber l'expression de C90rf72. Selon certains modes réalisation, la présente invention décrit des procédés de traitement de la sclérose latérale amyotrophique (SLA) et/ou de la démence frontotemporale (DFT).
PCT/US2023/071895 2022-08-09 2023-08-09 Identification de séquences cibles spécifiques d'allèles pour c9orf72 Ceased WO2024036186A2 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EP23853497.8A EP4569116A2 (fr) 2022-08-09 2023-08-09 Identification de séquences cibles spécifiques d'allèles pour c9orf72

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202263396545P 2022-08-09 2022-08-09
US63/396,545 2022-08-09

Publications (2)

Publication Number Publication Date
WO2024036186A2 true WO2024036186A2 (fr) 2024-02-15
WO2024036186A3 WO2024036186A3 (fr) 2024-05-16

Family

ID=89852488

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2023/071895 Ceased WO2024036186A2 (fr) 2022-08-09 2023-08-09 Identification de séquences cibles spécifiques d'allèles pour c9orf72

Country Status (2)

Country Link
EP (1) EP4569116A2 (fr)
WO (1) WO2024036186A2 (fr)

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11162096B2 (en) * 2013-10-14 2021-11-02 Ionis Pharmaceuticals, Inc Methods for modulating expression of C9ORF72 antisense transcript
JP6606557B2 (ja) * 2015-04-16 2019-11-13 アイオーニス ファーマシューティカルズ， インコーポレーテッド Ｃ９ｏｒｆ７２発現を調節するための組成物
US11260073B2 (en) * 2015-11-02 2022-03-01 Ionis Pharmaceuticals, Inc. Compounds and methods for modulating C90RF72
AU2020252020A1 (en) * 2019-03-29 2021-11-11 University Of Massachusetts Oligonucleotide-based modulation of C90RF72

Also Published As

Publication number Publication date
WO2024036186A3 (fr) 2024-05-16
EP4569116A2 (fr) 2025-06-18

Similar Documents

Publication Publication Date Title
US20240132892A1 (en) OLIGONUCLEOTIDE-BASED MODULATION OF C9orf72
JP7687685B2 (ja) 組織特異的なａｐｏｅ調節のためのオリゴヌクレオチド
CN102264903B (zh) 有效跳跃人杜兴肌营养不良前mRNA外显子45的方法和手段
US20250354148A1 (en) DUAL-ACTING siRNA BASED MODULATION OF C9orf72
US20090186410A1 (en) Rna silencing compositions and methods for the treatment of huntington's disease
US20120270930A1 (en) Methods and compositions for dysferlin exon-skipping
CN110799647A (zh) 双尾自递送sirna及相关的方法
US12258566B2 (en) Oligonucleotides for PRNP modulation
US20190142860A1 (en) Nucleic acid based tia-1 inhibitors
JP6987041B2 (ja) 脊髄性筋萎縮症におけるエクソン包含のための修飾アンチセンスオリゴマー
US12037585B2 (en) Oligonucleotides for tissue specific gene expression modulation
US11667920B2 (en) Methods for treating brain injury
CN104640988A (zh) siRNA及其在用于治疗和/或预防眼部病症的方法和组合物中的应用
WO2024036186A2 (fr) Identification de séquences cibles spécifiques d'allèles pour c9orf72
EP3691655B1 (fr) Molécule d'acide nucléique doté de propriétés anticoagulantes et anti-inflammatoires
WO2025151495A1 (fr) Inactivation spécifique d'allèle d'expression génique
US12163129B2 (en) Antisense oligonucleotides to restore dysferlin protein expression in dysferlinopathy patient cells
CN116490216A (zh) Sarna和mrna调节剂联合治疗sma
EP4446414A1 (fr) Complexe d'oligonucléotide antisens
WO2024263852A2 (fr) Compositions et procédés de modulation de l'expression de tau
WO2025151407A1 (fr) Compositions et méthodes pour moduler l'expression de l'alpha-synucléine
WO2025217494A1 (fr) Oligonucléotides à commutation d'épissage pour le traitement de troubles associés au gène cacna1a
WO2025128134A1 (fr) Crispri ciblant l'alpha-synucléine
WO2022035984A1 (fr) Oligonucléotides antisens pour le traitement d'affections et de maladies liées à trem2

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 23853497

Country of ref document: EP

Kind code of ref document: A2

WWE Wipo information: entry into national phase

Ref document number: 2023853497

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2023853497

Country of ref document: EP

Effective date: 20250310

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 23853497

Country of ref document: EP

Kind code of ref document: A2

WWP Wipo information: published in national office

Ref document number: 2023853497

Country of ref document: EP